Gyre Therapeutics (GYRE) Change in Account Payables (2014 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Change in Account Payables of $139000.0 for Q1 2026, up 892.86% year-over-year from $14000.0 in Q1 2025, and up 131.1% quarter-over-quarter from -$447000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Change in Account Payables (2014 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Change in Account Payables for 13 consecutive years, with $139000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 892.86% year-over-year to $139000.0; the TTM figure through Mar 2026 stood at $124000.0 (up 159.62% YoY), while the FY2025 annual figure was -$1000.0, up 99.59% from the prior year.
- Change in Account Payables advanced to $139000.0 in Q1 2026 per GYRE's latest filing, from -$447000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.3 million in Q4 2022 and bottomed at -$3.7 million in Q2 2022.
- Historically, Change in Account Payables has averaged -$1588.2 across 5 years, with a median of -$51000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 227.01% — and 2025, when it surged 1625.0%.
- Gyre Therapeutics' Change in Account Payables stood at $6.3 million in 2022, then slumped by 95.26% to $297000.0 in 2023, then slumped by 163.97% to -$190000.0 in 2024, then plunged by 135.26% to -$447000.0 in 2025, then surged by 131.1% to $139000.0 in 2026.
- Business Quant data shows GYRE's Change in Account Payables at $139000.0 in Q1 2026, -$447000.0 in Q4 2025, and $483000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 4.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.66 Mn |
| Jun 30, 2026 | 4.66 Mn |
| Mar 31, 2026 | 139,000.00 |
| Mar 31, 2026 | 139,000.00 |
| Dec 31, 2025 | -447,000.00 |
| Dec 31, 2025 | -447,000.00 |
| Sep 30, 2025 | 483,000.00 |
| Sep 30, 2025 | 483,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | -190,000.00 |
| Dec 31, 2024 | -190,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -23,000.00 |
| Mar 31, 2024 | -23,000.00 |